Department of Molecular Genetics, Aravind Medical Research Foundation, Madurai, Tamil Nadu, 625 020, India.
Department of Pathology, Aravind Eye Hospital, Madurai, Tamil Nadu, 625 020, India.
Curr Cancer Drug Targets. 2020;20(9):710-719. doi: 10.2174/1568009620666200504112711.
Retinoblastoma is a sight and life-threatening embryonal tumor in children. Though chemotherapy is the main mode of therapy, evolving resistance remains a major obstacle in treatment success. The presence of cancer stem cells (CSC) is frequently reported to be responsible for chemoresistance in multiple tumors.
Our study aims to identify the molecular factors that facilitate the chemoresistance through cancer stem cells in retinoblastoma.
We developed etoposide and carboplatin resistant retinoblastoma (Y79) cell lines by stepwise drug increment treatment, validated with MTT and TUNEL assays. Colony forming and invasive ability were studied by soft-agar colony forming and transwell assays, respectively. Similar analysis in non-responsive retinoblastoma tumors were carried out by histopathology. Finally, expression of CSC/neuronal markers and ABC transporters were examined by quantitative PCR and protein expression of neuronal stem cell markers was confirmed by Western blot.
Larger colony size of resistant cells in soft-agar assay provided evidence for increased selfrenewability. Histopathology in non-responsive tumors showed poorly differentiated cells predominantly. Besides, both resistant cell lines and non-responsive tumors showed increased invasion with higher expression of neuronal stem cell markers - SOX2, NANOG, OCT4 and ABC transporters - ABCB1 and ABCC3. Increased self-renewal ability and invasion along with overexpression of stemness markers in resistant cells and tumors provide evidence for stemness driving chemoresistance and invasion in retinoblastoma.
We have demonstrated Neuronal stem cell/CSC markers that facilitate the maintenance of cancer stem cells. Developing therapies targeting these factors will help in overcoming resistance and improving retinoblastoma treatment.
视网膜母细胞瘤是一种危及生命的儿童胚胎性肿瘤。虽然化疗是主要的治疗方式,但耐药性的出现仍然是治疗成功的主要障碍。研究表明,癌症干细胞(CSC)的存在常常导致多种肿瘤的化疗耐药。
本研究旨在鉴定通过视网膜母细胞瘤中的癌症干细胞促进化疗耐药的分子因素。
我们通过逐步药物递增处理,使用 MTT 和 TUNEL 测定法,开发了依托泊苷和顺铂耐药的视网膜母细胞瘤(Y79)细胞系。通过软琼脂集落形成和 Transwell 测定法分别研究了集落形成和侵袭能力。通过组织病理学对无反应性视网膜母细胞瘤肿瘤进行了类似的分析。最后,通过定量 PCR 检查了 CSC/神经元标记物和 ABC 转运体的表达,并通过 Western blot 证实了神经元干细胞标记物的蛋白表达。
软琼脂测定中耐药细胞的较大集落大小提供了自我更新能力增强的证据。无反应性肿瘤的组织病理学显示主要为分化不良的细胞。此外,耐药细胞系和无反应性肿瘤均表现出更高的侵袭性,同时神经元干细胞标记物 - SOX2、NANOG、OCT4 和 ABC 转运体 - ABCB1 和 ABCC3 的表达也增加。耐药细胞和肿瘤中自我更新能力的增强以及干性标记物的过度表达为干性驱动视网膜母细胞瘤的化疗耐药和侵袭提供了证据。
我们已经证明了神经干细胞/CSC 标记物有助于维持癌症干细胞。针对这些因素的治疗方法的开发将有助于克服耐药性并改善视网膜母细胞瘤的治疗。